The present study aims at measuring the effect of Trastuzumab in very small early breast cancers (pT1mic/a pN0/1mi) in terms of disease recurrence, and at identifying the factors that most affect the prognosis of small HER2+ tumors. Here, ERBB2 is linked to breast carcinoma.